Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer-Reference-Cited by-同舟云学术

Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer

Published:2022-06-17 Issue:2 Volume:24 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Lu Xiaojuan¹,Wan Junyan²,Shi Huaqiu³

Affiliation:

1. First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China

2. Department of Urology, People's Hospital of Leshan, Leshan, Sichuan 614000, P.R. China

3. Department of Oncology, The First Affiliated Hospital, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference49 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

3. Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer: Toward personalized medicine and combination strategies;Sui;J Immunol Res,2018

4. Immunotherapy rechallenge in patients with non-small-cell lung cancer;España;Pulmonology,2020

5. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: A systematic review and meta-analysis;Duan;JAMA Oncol,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events;World Journal of Gastrointestinal Oncology;2024-03-15

2. Progress in the Study of Serum Markers to Predict the Efficacy of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer;Advances in Clinical Medicine;2024

3. Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy;Frontiers in Immunology;2023-11-13

4. Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis;Clinical and Translational Oncology;2023-09-08

5. Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy;Frontiers in Oncology;2023-08-21